Merck’s WELIREG Secures Priority FDA Review for Adjuvant Treatment in Early RCC Driven by Pivotal DFS Improvement
Merck announced landmark results from its Phase 3 LITESPARK-022 trial, which evaluated the combination of KEYTRUDA (pembrolizumab) and WELIREG (belzutifan) as an adjuvant treatment for patients with certain types of earlier-stage renal cell carcinoma (RCC) at high risk of recurrence following nephrectomy. The study demonstrated that the combination therapy significantly reduced the risk of disease recurrence or death by 28% (Hazard Ratio = 0.72) compared to KEYTRUDA monotherapy.
This is particularly significant because KEYTRUDA alone is already...
